Takeda expands its rare diseases portfolio in India with the launch of Adynovate Adynovate in combination with MYPKFIT®, FDA approved application offers personalised and interactive prophylaxis treatment option…
Takeda launches mobile application to support patient for treatment of genetic diseases XPERT EASE safeguards dosage accuracy and reduces the incidence of error, thereby helping physicians develop personalised dosing…
Takeda launches Enzyme Replacement Therapy portfolio for lysosomal storage disorders in India Takeda brings to market Idursulfase for hunter syndrome, Velaglucerase Alpha for gaucher disease and Agalsidase Alfa for fabry…
